We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ARX:TSXARC Resources Ltd. Analysis

Data as of 2026-03-14 - not real-time

CA$27.57

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

ARC Resources is trading near the top of its 27‑month range at a price that sits below its DCF‑derived fair value, offering roughly a 4% upside. Technical indicators show a bullish MACD crossover and an RSI in the high‑60s, suggesting the stock is approaching overbought territory while still holding above the 20‑day SMA. The price‑to‑earnings multiple of about 12.6 is well under the industry average of 22, reinforcing the undervalued narrative. Recent material news includes a C$950 million senior note offering aimed at refinancing existing debt and an announced increase in the dividend, which improves yield sustainability. The company posted solid operating performance with revenue growth of roughly 16% and free cash flow exceeding C$800 million, supporting a 3% dividend yield and a modest payout ratio.
Fundamentally, ARC’s balance sheet shows a manageable debt‑to‑equity ratio for the sector, low beta (≈0.4) and a strong cash conversion profile, while the Montney asset base provides a stable geographic foothold. The combination of attractive valuation, sustainable dividend, and growth‑oriented cash flow targets positions the stock as a blend of value and growth, suitable for investors with a medium‑to‑long‑term horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI approaching overbought levels
  • Price near immediate resistance
  • Recent debt refinancing reduces near‑term financing risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervaluation relative to peers
  • Projected cash‑flow growth of ~16%
  • Sustainable 3% dividend yield

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Low beta and stable Canadian asset base
  • Continued dividend growth and payout stability
  • Long‑term upside from DCF fair‑value gap

Key Metrics & Analysis

Financial Health

Revenue Growth15.60%
Profit Margin20.99%
P/E Ratio12.6
ROE15.73%
ROA7.73%
Debt/Equity47.34
P/B Ratio1.9
Op. Cash FlowCA$3.1B
Free Cash FlowCA$822.8M
Industry P/E22.2

Technical Analysis

TrendNeutral
RSI68.5
SupportCA$23.83
ResistanceCA$27.98
MA 20CA$25.62
MA 50CA$24.93
MA 200CA$26.19
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueCA$30.38
Target PriceCA$28.68
Upside/Downside4.01%
GradeUndervalued
TypeBlend
Dividend Yield3.03%

Risk Assessment

Beta0.40
Volatility42.63%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.